文献速递神经免疫神经肌肉病

晚发型重症肌无力胸腺切除术的多中心纵向回顾性研究

Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.
PubMed 文献 · Ann Neurol · 2025-11-24

本研究基于多中心纵向临床数据库,比较晚发型重症肌无力(LOMG)患者接受胸腺切除术与单纯药物治疗的疗效差异。经倾向性评分匹配后,胸腺切除术组获得更好结局的机会是药物治疗组的2.356倍(95%CI=1.537-3.612,p<0.001)。手术不良事件发生率在LOMG与年轻MG患者间无显著差异(32.0% vs 22.4%,p=0.286)。

要点

  • 胸腺切除术可能为LOMG的有效治疗选择,但需随机对照试验进一步验证。
  • 匹配后胸腺切除术组获得更好结局的概率显著高于药物治疗组。
  • LOMG患者手术不良事件发生率与年轻MG患者相当。

核心结论

  • 胸腺切除术可能是晚发型重症肌无力的一种有效治疗选择。
  • 研究结果提示需要针对LOMG患者进一步开展随机对照试验。

研究设计与样本

  • 多中心纵向回顾性研究,从临床数据库筛选非胸腺瘤型乙酰胆碱受体抗体阳性LOMG患者。
  • 胸腺切除术组55例,药物治疗组210例,采用倾向性评分匹配、Kaplan-Meier分析和Cox回归模型比较两组。
  • 另比较LOMG患者与40至50岁年轻MG患者胸腺切除术不良事件发生率。

主要发现

  • 胸腺切除术组起病年龄显著低于药物治疗组(56.31±6.15 vs 62.04±7.83,p<0.001)。
  • 倾向性评分匹配调整后,胸腺切除术组获得更好结局的机会是药物治疗组的2.356倍(95%CI=1.537-3.612,p<0.001)。
  • 亚组分析中,胸腺切除术组在24±2个月时应答率显著高于药物治疗组(48.9%,95%CI=33.7-64.1% vs 23.8%,95%CI=14.2-33.3%,p=0.004)。
  • 胸腺切除术组在36±2个月时应答率亦显著高于药物治疗组(59.5%,95%CI=42.9-76.1% vs 28.9%,95%CI=18.5-39.4%,p=0.002)。
  • LOMG患者与年轻MG患者手术不良事件发生率相当(32.0% vs 22.4%,p=0.286)。

临床怎么用

  • 对于非胸腺瘤型AChR抗体阳性的LOMG患者,胸腺切除术可作为考虑的治疗选项之一。
  • 临床决策时需结合患者起病年龄及个体情况,并告知手术不良事件风险与年轻患者相当。

局限性

  • 本研究为回顾性研究,胸腺切除术组起病年龄显著低于药物治疗组,可能存在选择偏倚。
  • 样本量有限(胸腺切除术组55例),研究结果需随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Limited evidence has led to ongoing debate about the benefits of thymectomy for late-onset myasthenia gravis (LOMG). This study aims to compare the outcomes of patients with LOMG who underwent thymectomy versus those who received medical treatment alone, and evaluate the incidence of surgical adverse events. METHODS: Non-thymomatous acetylcholine-receptor antibody positive patients with LOMG were selected from a multi-center longitudinal clinical database. Rates of and time to response (remission and minimal manifestations status) were compared between 2 groups by propensity score matching (PSM), Kaplan-Meier analysis, and Cox regression models. Additionally, the incidence of adverse events about thymectomy was compared between LOMG and younger patients with myasthenia gravis (MG) aged 40 to 50 years old. RESULTS: A total of 55 and 210 patients with LOMG were enrolled in the thymectomy and medical treatment groups, respectively. The thymectomy group exhibited significantly younger onset age (56.31 ± 6.15 vs. 62.04 ± 7.83, p < 0.001). After PSM adjustment, thymectomy demonstrated a greater cumulative probability (p < 0.001), and the 2.356-fold (95% confidence interval [CI] = 1.537-3.612, p < 0.001) higher chance of better outcomes compared to medical treatment. In subgroup analysis, thymectomy showed significantly higher response rates compared to medical treatment alone at 24 ± 2 months (48.9%, 95% CI = 33.7-64.1% vs 23.8%, 95% CI = 14.2-33.3%, p = 0.004), and 36 ± 2 months (59.5%, 95% CI = 42.9-76.1% vs 28.9%, 95% CI = 18.5-39.4%, p = 0.002). The incidences of adverse events were comparable between patients with LOMG and younger patients with MG (32.0% vs 22.4%, p = 0.286). INTERPRETATION: Thymectomy may be an effective therapeutic option for LOMG. Our findings highlight the need for further development of a randomized trial targeting patients with LOMG. ANN NEUROL 2026;99:629-638.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Chen J, Su C, Feng L, et al. Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study. Ann Neurol. 2025. PMID: 41283202. doi:10.1002/ana.78093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。